Meeting
2022 ASCO Annual Meeting
AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC).
Authors
Jia Fan
Fudan University Zhongshan Hospital, Shanghai, China
Jia Fan , Zhenggang Ren , Chiun Hsu , Yabing Guo , Tianqiang Song , Wentao Wang , Yee Chao , Yujuan Gao , Vincent Li , Salvatore Ferro , Chia-Jui Yen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT04948697
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4172)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4172
Abstract #
TPS4172
Poster Bd #
151b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).
First Author: Jia Fan
Poster
2021 ASCO Annual Meeting
AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.
First Author: Sophia Frentzas
Poster
2021 ASCO Annual Meeting
AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).
First Author: Mark A. Socinski
Poster
2019 Gastrointestinal Cancers Symposium
Activation of central/effector memory T cells in advanced gastric cancer patients treated with antiprogrammed death-1 antibody.
First Author: Hirofumi Ohmura